Table 3. Multivariate analysis of the association of different factors and survival.
| Variable | Cancer-specific survival | Overall survival | ||
|---|---|---|---|---|
| Hazard ratio (95% confidence interval) | p-value | Hazard ratio (95% confidence interval) | p-value | |
| Age (>60 years old) | 1.01 (0.69–1.49) | 0.955 | 1.02 (0.70–1.49) | 0.923 |
| Sex (reference female) | 1.17 (0.69–2.00) | 0.565 | 1.26 (0.75–2.12) | 0.379 |
| Smoker | 1.16 (0.77–1.75) | 0.471 | 1.24 (0.84–1.85) | 0.282 |
| BMI (≥24.3 kg/m2) | 1.17 (0.80–1.70) | 0.432 | 1.14 (0.79–1.65) | 0.491 |
| Diabetes | 1.47 (0.86–2.51) | 0.164 | 1.40 (0.83–1.85) | 0.282 |
| Hypertension | 0.56 (0.35–0.89) | 0.015 | 0.60 (0.38–0.94) | 0.027 |
| Multifocality | 1.12 (0.77–1.62) | 0.561 | 1.07 (0.74–1.54) | 0.713 |
| Tumor size (≥3 cm)a | 1.07 (0.73–1.56) | 0.722 | 1.13 (0.78–1.63) | 0.521 |
| T1 vs. Ta | 3.19 (1.09–9.28) | 0.034 | 3.43 (1.18–9.95) | 0.023 |
| WHO high grade | 1.20 (0.75–1.92) | 0.440 | 1.26 (0.79–2.00) | 0.336 |
| CIS (no vs. yes) | 0.87 (0.57–1.35) | 0.539 | 0.87 (0.57–1.33) | 0.519 |
| IVT (no vs. yes) | 1.02 (0.70–1.49) | 0.918 | 1.06 (0.73–1.54) | 0.753 |
| PNLR >2.2 | 2.87 (1.96–4.18) | <0.001 | 2.83 (1.96–4.07) | <0.001 |
BMI, body mass index; WHO, World Health Organization; CIS, carcinoma in situ; IVT, Intravesical therapy; PNLR, preoperative neutrophil-to-lymphocyte ratio.
a:For multiple tumors, the diameter of the largest tumor was regarded as tumor size.